Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive save search
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
OCUL | News | $5.86 -22.69% -29.35% 6.1M
|
Health Technology
|
| O: -5.78%
H: 0.0%
C: 0.0%
ocular positive for topline diabetic
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
|
| O: 5.41%
H: 41.06%
C: 29.66%
bb-301 first positive biopharma for trial opmd study
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Published: 2024-04-18 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.51 -5.63% -5.96% 270K
|
|
| O: -0.63%
H: 1.89%
C: -4.4%
neurology presentation readout positive topline meeting
LinkShadow is positioned as a Representative Vendor in the 2024 Gartner® Market Guide for Network Detection and Response (NDR)
Published: 2024-04-18 (Crawled : 14:00) - prnewswire.com
IT | News | $449.61 0.07% 0.0% 390K
|
Commercial Services
|
| O: -0.15%
H: 0.0%
C: 0.0%
gartner for network response market
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | News | $42.16 1.35% 1.33% 1.3M
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Zscaler Positioned as a Leader in the 2024 Gartner® Magic Quadrant™ for Security Service Edge (SSE) for Third Straight Year
Published: 2024-04-18 (Crawled : 19:00) - globenewswire.com
IT | News | $449.61 0.07% 0.0% 390K
|
Commercial Services
| Email alert
Add to watchlist
ZS | News | $172.79 -0.1% -0.1% 1.7M
|
Technology Services
| Email alert
Add to watchlist
gartner service year security for
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.75%
H: 0.0%
C: 0.0%
rinvoq positive cell results study
BranchOut Food Strengthens Financial Position with Successful Sale of Senior Secured Promissory Notes and Warrants
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
BOF | $1.1 -5.17% -5.45% 5.6K
|
| Email alert
Add to watchlist
food financial
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
IMMP | News | $2.205 -2.43% -2.73% 270K
|
Health Technology
|
| O: -6.87%
H: 0.0%
C: 0.0%
tacti-004 lung positive cancer cell for trial
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.69 0.0% 230K
|
|
| O: 9.85%
H: 4.63%
C: -18.04%
fda positive pharmaceuticals for technology response
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI | News 0 d | $72.01 -6.1% -6.5% 4.7M
|
Health Technology
|
| O: 14.75%
H: 12.75%
C: 6.04%
positive topline therapy results study
Blue Biofuels Initiates Engineering and Design for Their CTS Commercial Plant Positioned to Produce Ethanol from Cellulosic Materials
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
BIOF | $0.0877 34.16% 80K
|
Information
|
| O: 0.36%
H: 6.02%
C: 5.9%
for commercial design blue
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Published: 2024-04-16 (Crawled : 13:00) - globenewswire.com
MYGN F | $18.51 -0.7% -0.7% 640K
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
prequel positive for study
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
TFFP | $3.2405 -9.69% 26K
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: -11.56%
tacrolimus presentation positive sessions pharmaceuticals trial
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE F | $43.38 -1.65% -1.68% 770K
|
Health Technology
|
| O: -10.79%
H: 0.0%
C: -3.75%
gtx-102 positive treatment
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.195 6.7% 6.28% 580K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
MS | News 0 d | $90.26 0.2% 0.0% 6.7M
|
Finance
|
| O: -0.74%
H: 0.09%
C: -5.32%
LPCN | $5.47 2.82% 2.74% 21K
|
Health Technology
|
| O: 6.78%
H: 13.49%
C: 1.75%
obesity positive results
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $2.97 4.58% 4.38% 150K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
DARE | $0.299 5.77% 5.45% 970K
|
Health Technology
|
| O: 1.36%
H: 0.68%
C: -0.64%
ovaprene test positive bioscience publication contraceptive contraception study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.